<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Cardiol Congenit Heart Dis</journal-id><journal-id journal-id-type="iso-abbrev">Int J Cardiol Congenit Heart Dis</journal-id><journal-title-group><journal-title>International Journal of Cardiology Congenital Heart Disease</journal-title></journal-title-group><issn pub-type="epub">2666-6685</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">37435574</article-id><article-id pub-id-type="pmc">PMC10335194</article-id><article-id pub-id-type="pii">S2666-6685(22)00037-4</article-id><article-id pub-id-type="doi">10.1016/j.ijcchd.2022.100354</article-id><article-id pub-id-type="publisher-id">100354</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Maternal and fetal outcomes in pregnant women with pulmonary hypertension: The impact of left heart disease</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Marshall V</surname><given-names>William H.</given-names></name><email>William.marshall@osumc.edu</email><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Gee</surname><given-names>Stephen</given-names></name><xref rid="aff3" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Lim</surname><given-names>Woobeen</given-names></name><xref rid="aff4" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Lastinger</surname><given-names>Lauren T.</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Cackovic</surname><given-names>Michael</given-names></name><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Benza</surname><given-names>Raymond L.</given-names></name><xref rid="aff1" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Daniels</surname><given-names>Curt J.</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au8"><name><surname>Bradley</surname><given-names>Elisa A.</given-names></name><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au9"><name><surname>Rajpal</surname><given-names>Saurabh</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref></contrib><aff id="aff1"><label>a</label>The Ohio State University Wexner Medical Center, Department of Internal Medicine, Division of Cardiovascular Medicine, Columbus, OH, United States</aff><aff id="aff2"><label>b</label>Nationwide Children's Hospital, Heart Center, Columbus, OH, United States</aff><aff id="aff3"><label>c</label>Ohio Health, Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Columbus, OH, United States</aff><aff id="aff4"><label>d</label>The Ohio State University, College of Public Health, Division of Biostatistics, Columbus, OH, United States</aff><aff id="aff5"><label>e</label>The Ohio State University Wexner Medical Center, Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Columbus, OH, United States</aff><aff id="aff6"><label>f</label>Penn State Health Heart and Vascular Institute, Hershey S. Milton Medical Center, Hershey, PA, United States</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author. Davis Heart and Lung Research Institute, Wexner Medical Center at The Ohio State University, Division of Cardiovascular Medicine, 473 W. 12th Avenue Suite 200, Columbus, OH, 43210, United States. <email>William.marshall@osumc.edu</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>24</day><month>2</month><year>2022</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>6</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>24</day><month>2</month><year>2022</year></pub-date><volume>8</volume><elocation-id>100354</elocation-id><history><date date-type="received"><day>23</day><month>3</month><year>2021</year></date><date date-type="rev-recd"><day>16</day><month>12</month><year>2021</year></date><date date-type="accepted"><day>21</day><month>2</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; 2022 The Authors</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0010"><sec><title>Background</title><p>Pulmonary hypertension (PH) due to left heart disease (World Health Organization (WHO) Group 2&#x000a0;PH) is the largest PH subgroup, however most reports of PH in pregnancy focus on patients with pulmonary arterial hypertension (WHO Group 1&#x000a0;PH). We evaluated pregnancy outcomes across WHO PH subgroups.</p></sec><sec><title>Methods</title><p>We performed a retrospective single center cohort study of maternal and fetal outcomes in pregnant women with PH (2004&#x02013;2018).</p></sec><sec><title>Results</title><p>We analyzed outcomes of 70 pregnancies in 70 women with PH (30&#x000a0;&#x000b1;&#x000a0;6 years-old), classified as WHO Group 1&#x000a0;PH (12 (17%)), Group 2&#x000a0;PH (45 (64%)), Group 3&#x000a0;PH (4 (6%)) and Group 5&#x000a0;PH (9 (13%)). Although no peripartum death occurred, 3 (4.3%) women with WHO Group 2&#x000a0;PH had late mortality (7&#x000a0;&#x000b1;&#x000a0;4 months post-partum). Additionally, 33 major adverse cardiac events occurred in 26 (37%) women, preterm birth occurred in 32 (49%), and post-partum hemorrhage in 10 (14%), such that only 24 (37%) women completed a viable pregnancy free of an adverse cardiac, obstetric or fetal/neonatal event. Major adverse cardiac events were predominantly due to heart failure (24 (73%)), occurring only in WHO Groups 1 and 2&#x000a0;PH (3 (25%) women vs. 17 (38%), p&#x000a0;=&#x000a0;0.07), and significantly associated with pre-eclampsia, left ventricular ejection fraction &#x02264;45%, maternal diabetes, and systemic hypertension.</p></sec><sec><title>Conclusions</title><p>WHO Group 2&#x000a0;PH carries similar risk for maternal cardiovascular events when compared to women with WHO Group 1&#x000a0;PH. Further studies evaluating maternal risk in this cohort are needed.</p></sec></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Pregnancy</kwd><kwd>Pulmonary hypertension</kwd><kwd>Heart failure</kwd><kwd>High-risk obstetrics</kwd></kwd-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0010">Pulmonary hypertension (PH) is defined as a mean pulmonary artery pressure of &#x0003e;20&#x000a0;mmHg on cardiac catheterization, and is estimated to affect approximately 9% of the general population [<xref rid="bib1" ref-type="bibr">1</xref>]. PH is classified into five World Health Organization (WHO) groups based on the etiology of pulmonary artery pressure elevation: pulmonary arterial hypertension (WHO Group 1&#x000a0;PH), PH due to left heart disease (WHO Group 2&#x000a0;PH), PH due to chronic lung disease (WHO Group 3&#x000a0;PH), PH due to chronic thromboembolic disease (WHO Group 4&#x000a0;PH) and PH due to multifactorial mechanisms (WHO Group 5&#x000a0;PH) [<xref rid="bib2" ref-type="bibr">2</xref>].</p><p id="p0015">Historically, maternal mortality with pregnancy in the setting of WHO Group 1&#x000a0;PH has been reported as high as 30&#x02013;56% [<xref rid="bib4" ref-type="bibr">4</xref>]; therefore, pregnancy in women with PH is contraindicated according to the modified WHO classification system of maternal risk [<xref rid="bib3" ref-type="bibr">3</xref>]. Despite progress in PH care and maternal fetal medicine, cardiovascular disease remains the most common cause of maternal morbidity and mortality in the United States [<xref rid="bib5" ref-type="bibr">5</xref>]. In part, this may be attributed to more women pursuing pregnancy in advanced maternal age and with increasingly complex cardiovascular disease, such as PH [<xref rid="bib6" ref-type="bibr">6</xref>,<xref rid="bib7" ref-type="bibr">7</xref>]. However, while WHO Group 2 is the most common subgroup of PH [<xref rid="bib1" ref-type="bibr">1</xref>], the majority of data on pregnancy outcomes in PH focus on WHO Group 1&#x000a0;PH [<xref rid="bib8" ref-type="bibr">[8]</xref>, <xref rid="bib9" ref-type="bibr">[9]</xref>, <xref rid="bib10" ref-type="bibr">[10]</xref>]. Individual maternal risk in WHO non-Group 1&#x000a0;PH has not been robustly reported. Therefore, we sought to define maternal major adverse cardiovascular events (MACE), obstetric and fetal outcomes, across WHO PH groups.</p></sec><sec id="sec2"><label>2</label><title>Methods</title><sec id="sec2.1"><label>2.1</label><title>Study design</title><p id="p0020">We performed a single center retrospective cohort study of pregnant women with right ventricular systolic pressure (RVSP)&#x000a0;&#x0003e;35&#x000a0;mm of mercury (mmHg) or a tricuspid regurgitation velocity &#x02265;2.8&#x000a0;m per second (m/s) on transthoracic echocardiogram (TTE) (November 2011&#x02013;April 2018). We also included patients with a known diagnosis of PH who were clinically cared for in our cardio-obstetrics clinic (November 2004&#x02013;April 2018). The Ohio State University's Biomedical Institutional Review Board approved this study with waivered consent.</p></sec><sec id="sec2.2"><label>2.2</label><title>Patient identification, classification and data collection</title><p id="p0025">Inclusion criteria consisted of: TTE completed during pregnancy and presence of confirmed PH (mean pulmonary artery pressure &#x0003e;20&#x000a0;mmHg on hemodynamic catheterization) or TTE findings consistent with intermediate to high probability PH based on European Society of Cardiology (ESC) guidelines. ESC guidelines utilize tricuspid regurgitation velocity over RVSP, with the addition of right ventricular dysfunction or enlargement on TTE to determine PH probability [<xref rid="bib11" ref-type="bibr">11</xref>]. Exclusion criteria consisted of: cardiology evaluation indicating that the right ventricular systolic pressure (RVSP) was over-estimated on TTE, right ventricular outflow tract obstruction, hemodynamic catheterization excluding PH [<xref rid="bib2" ref-type="bibr">2</xref>], elevated RVSP during critical illness that resolved, or low probability for PH based on ESC guidelines [<xref rid="bib11" ref-type="bibr">11</xref>]. Baseline characteristics were collected from the medical record and are also outlined in the supplemental methods.</p><p id="p0030">Women were classified into WHO PH subgroups based on the most recent consensus definitions [<xref rid="bib2" ref-type="bibr">2</xref>], which was determined by cardiac catheterization or medical record diagnosis by a cardiologist or PH specialist in the majority of women, including all women with Group 1&#x000a0;PH. Catheterization for other PH subgroups is a class IIb recommendation [<xref rid="bib11" ref-type="bibr">11</xref>]. Therefore, in this real-world cohort where pregnant women with clinical features consistent with non-Group 1&#x000a0;PH are unlikely to undergo catheterization, the remaining women identified with PH by echocardiogram were classified based on analysis of typical echocardiographic findings and extensive chart review of risk factors by authors with expertise in PH. The described method is similar to prior studies and based on consensus documentation [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib12" ref-type="bibr">[12]</xref>, <xref rid="bib13" ref-type="bibr">[13]</xref>, <xref rid="bib14" ref-type="bibr">[14]</xref>]. The supplemental methods provide a detailed description of the criteria used to assign PH subgroups.</p></sec><sec id="sec2.3"><label>2.3</label><title>Outcomes studied</title><p id="p0035">Maternal cardiac outcomes included: mortality at 1-year post-partum, MACE and any arrhythmia. MACE was defined as maternal death during pregnancy or up to 42 days post-partum [<xref rid="bib15" ref-type="bibr">15</xref>]; hospital admission for decompensated heart failure requiring either intravenous diuretics, inotropes or mechanical circulatory support; myocardial infarction; thromboembolism; sustained (&#x0003e;30&#x000a0;seconds) ventricular arrhythmias; cardiac transplant; or need for invasive cardiac intervention (valve replacement or coronary intervention). Decompensated heart failure was defined as inpatient admission during pregnancy or up to 6 weeks post-partum requiring diuretic therapy, use of inotropes, temporary mechanical circulatory support, or documentation of heart failure or cardiogenic shock in the medical record. Maternal obstetric outcomes included: pre-eclampsia, defined by medical record diagnosis in pregnancies beyond 20 weeks gestation; cesarean delivery (CD); and post-partum hemorrhage, based on the standard definition [<xref rid="bib16" ref-type="bibr">16</xref>]. Fetal outcomes included: miscarriage and still birth, defined as loss of a pregnancy at less or greater than 20 weeks gestational age, respectively; preterm birth, by WHO definitions [<xref rid="bib17" ref-type="bibr">17</xref>]; low birth weight (&#x0003c;2500&#x000a0;grams); and neonatal mortality, defined as mortality at less than 30 days after a live birth. Outcome definitions are further detailed in the supplemental methods. We evaluated maternal and fetal outcomes between WHO PH groups.</p></sec><sec id="sec2.4"><label>2.4</label><title>Statistical analysis</title><p id="p0040">Baseline characteristics and outcomes are reported and compared for all patients, with further categorization based upon WHO PH subgroup. Categorical data are presented as frequencies and percentages, compared using chi-square. If there were &#x0003c;5 cases per group, Fisher's exact test was used. Continuous variables are presented as mean&#x000a0;&#x000b1;&#x000a0;standard deviation with differences assessed using ANOVA when normality assumption was satisfied using Shapiro-Wilk test. In the case of non-normally distributed data, the Kruskal-Wallis rank sum test was performed. Univariate logistic regression was used to investigate the association between the clinical variables and outcomes. <italic>P</italic>-values &#x02264; 0.05 (two-sided test) were considered statistically significant. Analyses were performed with R-3.6.1 (R Core Team (2013), Vienna, Austria).</p></sec></sec><sec id="sec3"><label>3</label><title>Results</title><sec id="sec3.1"><label>3.1</label><title>Baseline characteristics</title><p id="p0045">We evaluated 143 women with known PH and/or evidence of elevated RVSP on TTE. From that cohort, 70 women (mean age 30&#x000a0;&#x000b1;&#x000a0;6 years-old) met inclusion criteria (<xref rid="fig1" ref-type="fig">Fig. 1</xref>), and were classified as having WHO Group 1&#x000a0;PH (12 (17%)), Group 2&#x000a0;PH (45 (64%)), Group 3&#x000a0;PH (4 (6%)) or Group 5&#x000a0;PH (9 (13%)) as described in the supplemental methods (<xref rid="appsec1" ref-type="sec">Table S1</xref>). There were not any women who met clinical criteria for classification as Group 4&#x000a0;PH (supplemental methods). The etiology of PH in each subgroup is outlined in <xref rid="fig1" ref-type="fig">Fig. 1</xref>, with baseline characteristics detailed in <xref rid="tbl1" ref-type="table">Table 1</xref> and <xref rid="appsec1" ref-type="sec">Table S2</xref>.<fig id="fig1"><label>Fig. 1</label><caption><p>Study design, inclusion and exclusion criteria and World Health Organization (WHO) pulmonary hypertension (PH) groups. Etiology of PH and number of patients are listed below each WHO PH group. RVSP indicates right ventricular systolic pressure; TR, tricuspid regurgitation; mmHg, millimeters of mercury; m/s, meters per second; ESC, European Society of Cardiology; WSPH, World Society of Pulmonary Hypertension; PAH, pulmonary arterial hypertension; CHD, congenital heart disease; TOF, Tetralogy of Fallot; RV, right ventricle; PA, Pulmonary Artery; VSD, ventricular septal defect; ES, Eisenmenger Syndrome; ASD, atrial septal defect; HFrEF, heart failure with reduced ejection fraction; PPCM, peripartum cardiomyopathy; ICM, ischemic cardiomyopathy; CM, cardiomyopathy; DCM, dilated cardiomyopathy; NICM; non-ischemic cardiomyopathy; HFpEF, heart failure with preserved ejection fraction; HCM, hypertrophic cardiomyopathy; ILD, interstitial lung disease; COPD, chronic obstructive pulmonary disease; OSA, obstructive sleep apnea; BAV, bicuspid aortic valve; TV, tricuspid valve; TAPVR, total anomalous pulmonary venous return; d-TGA, dextro-transposition of great arteries. * Other includes non-compaction cardiomyopathy (n&#x000a0;=&#x000a0;1), high output heart failure (n&#x000a0;=&#x000a0;2) and women with 2 or more cardiac risk factors for left heart disease as outlined by the World Society of Pulmonary Hypertension (n&#x000a0;=&#x000a0;9).</p></caption><alt-text id="alttext0015">Fig. 1</alt-text><graphic xlink:href="gr1"/></fig><table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Baseline characteristics of pregnant women with pulmonary hypertension.</p></caption><alt-text id="alttext0035">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th/><th>All Patients (n&#x000a0;=&#x000a0;70)<xref rid="tbl1fna" ref-type="table-fn">a</xref></th><th>Group 1&#x000a0;PH (n&#x000a0;=&#x000a0;12)<xref rid="tbl1fnb" ref-type="table-fn">b</xref></th><th>Group 2&#x000a0;PH (n&#x000a0;=&#x000a0;45)<xref rid="tbl1fnc" ref-type="table-fn">c</xref></th><th>Group 3&#x000a0;PH (n&#x000a0;=&#x000a0;4)</th><th>Group 5&#x000a0;PH (n&#x000a0;=&#x000a0;9)</th><th>p-value (all PH Groups)</th><th>p-value (Group 1&#x000a0;PH vs Group 2&#x000a0;PH)</th></tr></thead><tbody><tr><td colspan="8" align="left">Clinical Variables, n (%)</td></tr><tr><td align="left">Age (years)</td><td align="left">30 (6)</td><td align="left">28 (7)</td><td align="left">30 (6)</td><td align="left">29 (7)</td><td align="left">30 (6)</td><td align="left">0.86</td><td align="left">0.33</td></tr><tr><td align="left">Body mass index (kg/m<sup>2</sup>)</td><td align="left">33 (11)</td><td align="left">29 (8)</td><td align="left">35 (12)</td><td align="left">34 (11)</td><td align="left">27 (3)</td><td align="left">0.12</td><td align="left">0.08</td></tr><tr><td align="left">Maternal race</td><td/><td/><td/><td/><td/><td align="left">0.05</td><td align="left">0.02</td></tr><tr><td align="left">&#x000a0;Non-Hispanic White</td><td align="left">36 (52)</td><td align="left">8 (66)</td><td align="left">24 (53)</td><td align="left">1 (25)</td><td align="left">3 (33)</td><td/><td/></tr><tr><td align="left">&#x000a0;Non-Hispanic Black</td><td align="left">29 (42)</td><td align="left">2 (17)</td><td align="left">19 (42)</td><td align="left">2 (50)</td><td align="left">6 (67)</td><td/><td/></tr><tr><td align="left">&#x000a0;Hispanic</td><td align="left">2 (3)</td><td align="left">0 (0)</td><td align="left">2 (4)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td/><td/></tr><tr><td align="left">&#x000a0;Other</td><td align="left">2 (3)</td><td align="left">2 (17)</td><td align="left">0 (0)</td><td align="left">1 (25)</td><td align="left">0 (0)</td><td/><td/></tr><tr><td align="left">Gravid</td><td align="left">3 (2)</td><td align="left">2 (1)</td><td align="left">3 (2)</td><td align="left">4 (2)</td><td align="left">3 (3)</td><td align="left">0.22</td><td align="left">0.01</td></tr><tr><td align="left">Para</td><td align="left">2 (2)</td><td align="left">1 (0)</td><td align="left">3 (2)</td><td align="left">3 (2)</td><td align="left">2 (1)</td><td align="left">0.07</td><td align="left">0.03</td></tr><tr><td align="left">Systemic hypertension</td><td align="left">32 (46)</td><td align="left">2 (16)</td><td align="left">29 (64)</td><td align="left">1 (25)</td><td align="left">0 (0)</td><td align="left">&#x0003c;0.01</td><td align="left">0.01</td></tr><tr><td align="left">Diabetes</td><td align="left">15 (21)</td><td align="left">0 (0)</td><td align="left">14 (31)</td><td align="left">1 (25)</td><td align="left">0 (0)</td><td align="left">0.04</td><td align="left">0.07</td></tr><tr><td align="left">Sleep apnea</td><td align="left">5 (7)</td><td align="left">1 (8)</td><td align="left">2 (4)</td><td align="left">2 (50)</td><td align="left">0 (0)</td><td align="left">0.01</td><td align="left">1</td></tr><tr><td align="left">Smoking history</td><td align="left">35 (50)</td><td align="left">6 (50)</td><td align="left">24 (53)</td><td align="left">2 (50)</td><td align="left">3 (33)</td><td align="left">0.75</td><td align="left">1</td></tr><tr><td align="left">Serum creatinine (mg/dL)</td><td align="left">0.7 (0.3)</td><td align="left">0.6 (0.2)</td><td align="left">0.8 (0.4)</td><td align="left">0.6 (0.4)</td><td align="left">0.5 (0.1)</td><td align="left">0.11</td><td align="left">0.16</td></tr><tr><td align="left">NYHA-FC (in pregnancy)</td><td/><td/><td/><td/><td/><td align="left">0.04</td><td align="left">0.05</td></tr><tr><td align="left">&#x000a0;1</td><td align="left">30 (43)</td><td align="left">1 (8)</td><td align="left">22 (49)</td><td align="left">1 (25)</td><td align="left">6 (67)</td><td/><td/></tr><tr><td align="left">&#x000a0;2</td><td align="left">16 (23)</td><td align="left">6 (50)</td><td align="left">7 (16)</td><td align="left">0 (0)</td><td align="left">3 (33)</td><td/><td/></tr><tr><td align="left">&#x000a0;3</td><td align="left">17 (24)</td><td align="left">4 (34)</td><td align="left">11 (24)</td><td align="left">2 (50)</td><td align="left">0 (0)</td><td/><td/></tr><tr><td align="left">&#x000a0;4</td><td align="left">6 (9)</td><td align="left">1 (8)</td><td align="left">4 (9)</td><td align="left">1 (25)</td><td align="left">0 (0)</td><td/><td/></tr><tr><td colspan="8" align="left">Management (n, %)</td></tr><tr><td align="left">Pulmonary vasodilators</td><td align="left">10 (15)</td><td align="left">10 (83)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">&#x0003c;0.01</td><td align="left">&#x0003c;0.01</td></tr><tr><td align="left">Anticoagulation</td><td align="left">13 (19)</td><td align="left">7 (64)</td><td align="left">3 (7)</td><td align="left">0 (0)</td><td align="left">3 (33)</td><td align="left">0.02</td><td align="left">&#x0003c;0.01</td></tr><tr><td align="left">Antiplatelet</td><td align="left">12 (18)</td><td align="left">3 (27)</td><td align="left">9 (21)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0.47</td><td/></tr><tr><td align="left">Nitrate/Hydralazine</td><td align="left">5 (7)</td><td align="left">0 (0)</td><td align="left">5 (11)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0.41</td><td align="left">0.57</td></tr><tr><td align="left">Beta Blocker</td><td align="left">22 (31)</td><td align="left">0 (0)</td><td align="left">18 (40)</td><td align="left">1 (25)</td><td align="left">3 (33)</td><td align="left">0.09</td><td align="left">0.03</td></tr><tr><td align="left">Diuretic</td><td align="left">11 (16)</td><td align="left">3 (25)</td><td align="left">8 (18)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0.3</td><td align="left">0.77</td></tr></tbody></table><table-wrap-foot><fn><p>Continuous variables are presented as mean (standard deviation). PH indicates pulmonary hypertension; kg/m<sup>2</sup>, kilograms per meter squared; NYHA-FC, New York Heart Association Functional Class; mg, milligrams; dL, deciliter.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fna"><label>a</label><p id="ntpara0010">Unknown in all PH patients: NYHA-FC, n&#x000a0;=&#x000a0;1; Pulmonary vasodilator use, n&#x000a0;=&#x000a0;1; anticoagulation use, n&#x000a0;=&#x000a0;2; antiplatelet use, n&#x000a0;=&#x000a0;2.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnb"><label>b</label><p id="ntpara0015">Unknown in Group 1&#x000a0;PH: anticoagulation use, n&#x000a0;=&#x000a0;1; antiplatelet use, n&#x000a0;=&#x000a0;1.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnc"><label>c</label><p id="ntpara0020">Unknown in Group 2&#x000a0;PH: NYHA-FC, n&#x000a0;=&#x000a0;1; Pulmonary vasodilator use, n&#x000a0;=&#x000a0;1; anticoagulation use, n&#x000a0;=&#x000a0;1; antiplatelet use, n&#x000a0;=&#x000a0;1.</p></fn></table-wrap-foot></table-wrap></p><p id="p0050">Women with Group 1&#x000a0;PH demonstrated higher RVSP at baseline (<xref rid="fig2" ref-type="fig">Fig. 2</xref>A), more right ventricular enlargement and had a higher proportion with right ventricular dysfunction (<xref rid="appsec1" ref-type="sec">Table S2</xref>). Intravenous prostacyclin therapy was prescribed only to women with Group 1&#x000a0;PH (10 (83%)), with 4 (33%) of those women on dual therapy with both prostacyclin and a phosphodiesterase 5 inhibitor. A pre-pregnancy diagnosis of PH was more common in Group 1&#x000a0;PH than Group 2&#x000a0;PH (9 (75%) vs. 12 (27%), p&#x000a0;=&#x000a0;0.01) (<xref rid="appsec1" ref-type="sec">Table S2</xref>), whereas a pre-pregnancy diagnosis of systemic hypertension and diabetes were more common in Group 2&#x000a0;PH (<xref rid="tbl1" ref-type="table">Table 1</xref>). The left ventricular ejection fraction (LVEF) was similar in all groups, though significantly lower when Group 2 (50&#x000a0;&#x000b1;&#x000a0;14%) was compared to Group 1 (59&#x000a0;&#x000b1;&#x000a0;6%, p = 0.02, <xref rid="appsec1" ref-type="sec">Table S2</xref>); this was due to 16 (36%) women in Group 2&#x000a0;PH with left ventricular (LV) systolic dysfunction (LVEF &#x0003c;50%), with mean time from diagnosis of LV dysfunction to delivery of 62&#x000a0;&#x000b1;&#x000a0;126 weeks (<xref rid="fig2" ref-type="fig">Fig. 2</xref>B, <xref rid="appsec1" ref-type="sec">Table S2</xref>, <xref rid="appsec1" ref-type="sec">Table S3</xref>). Beta blockers were used in 22 (31%) women (<xref rid="tbl1" ref-type="table">Table 1</xref>), including 6 (38%) with LV systolic dysfunction. Further medical therapy is described in <xref rid="tbl1" ref-type="table">Table 1</xref> and <xref rid="appsec1" ref-type="sec">Table S4</xref>.<fig id="fig2"><label>Fig. 2</label><caption><p>Echocardiographic and catheterization data for pregnant women with pulmonary hypertension (PH) by World Health Organization (WHO) PH group. <bold>(A)</bold> Right ventricular systolic pressure (RVSP) was highest in Group 1&#x000a0;PH (p&#x000a0;&#x0003c;&#x000a0;0.01). <bold>(B)</bold> Left ventricular ejection fraction (LVEF) was similar between WHO PH subgroups (p&#x000a0;=&#x000a0;0.12). Catheterization data was available for 26 (37%) with <bold>(C)</bold> mean pulmonary artery pressure (PAP) and <bold>(D)</bold> pulmonary capillary wedge pressure (PCWP) or left ventricular end diastolic pressure (LVEDP) presented for each WHO PH group. mmHg indicates millimeters of mercury. *Indicates p&#x000a0;&#x02264;&#x000a0;0.05.</p></caption><alt-text id="alttext0020">Fig. 2</alt-text><graphic xlink:href="gr2"/></fig></p><p id="p0055">Invasive hemodynamic data was available in 26 (37%) women, including all 12 (100%) women with Group 1&#x000a0;PH (<xref rid="fig2" ref-type="fig">Fig. 2</xref>C/D, <xref rid="appsec1" ref-type="sec">Table S2</xref>). In the 8 (31%) women who underwent catheterization during pregnancy (at a mean gestational age of 27&#x000a0;&#x000b1;&#x000a0;8 weeks), catheterization was performed to confirm the diagnosis of PH in 4 (50%) women (Group 1&#x000a0;PH (n&#x000a0;=&#x000a0;2), Group 2&#x000a0;PH (n&#x000a0;=&#x000a0;1) and Group 5&#x000a0;PH (n&#x000a0;=&#x000a0;1)), and in the other 4 (50%) women (all Group 1&#x000a0;PH), to assess baseline hemodynamics prior to initiation of prostacyclin therapy. While the majority of women (52 (74%)) were evaluated by a cardiologist at least once either pre-pregnancy, during pregnancy or immediately post-partum (<xref rid="appsec1" ref-type="sec">Table S2</xref>), only 31 (44%) women received formal cardio-obstetrics care, more commonly in Group 1&#x000a0;PH (Group 1&#x000a0;PH (10 (83%)) vs. Group 2&#x000a0;PH (16 (36%)), Group 3&#x000a0;PH (1 (25%)), Group 5&#x000a0;PH (4 (44%)), p&#x000a0;=&#x000a0;0.02).</p></sec><sec id="sec3.2"><label>3.2</label><title>Maternal cardiac outcomes</title><p id="p0060">There were no maternal deaths during pregnancy; however, there were 3 late post-partum deaths in women with Group 2&#x000a0;PH (7&#x000a0;&#x000b1;&#x000a0;4 months post-partum, 1-year mortality rate: 4.3%), which are detailed in <xref rid="tbl2" ref-type="table">Table 2</xref>. There were 33 MACE in 26 (37%) women, with 18 (55%) in the antepartum period, 9 (27%) intrapartum and 6 (18%) post-partum. MACE was similar between WHO PH subgroups (<xref rid="tbl3" ref-type="table">Table 3</xref>), and described in detail in <xref rid="tbl4" ref-type="table">Table 4</xref>, and <xref rid="fig3" ref-type="fig">Fig. 3</xref>A/B. The most common type of MACE (73%) observed was admission for heart failure (n&#x000a0;=&#x000a0;24), which occurred in 20 (29%) women; only women in Groups 1 and 2&#x000a0;PH were admitted for heart failure, with no difference between the 2 groups (Group 1&#x000a0;PH (3 admissions in 3 (25%) women) vs. Group 2&#x000a0;PH (21 admissions in 17 (38%) women), p&#x000a0;=&#x000a0;0.07). Importantly, 10 (42%) of the heart failure admissions occurred in 9 women with Group 2&#x000a0;PH who had LV dysfunction, of which the majority (n&#x000a0;=&#x000a0;8, 88%) were first diagnosed with LV dysfunction within 6 weeks of delivery (<xref rid="appsec1" ref-type="sec">Table S3</xref>). Other MACE included thromboembolism in 6 (9%) women, myocardial infarction due to spontaneous coronary artery dissection in 1 woman, and urgent valvular interventions in 2 women (<xref rid="tbl3" ref-type="table">Table 3</xref>, <xref rid="tbl4" ref-type="table">Table 4</xref>, <xref rid="fig3" ref-type="fig">Fig. 3</xref>A/B). Arrhythmias occurred in 5 (7%) however no fatal or sustained ventricular arrhythmias occurred in the cohort (<xref rid="appsec1" ref-type="sec">Table S5</xref>). On univariate analysis, MACE occurred more often in women with pre-eclampsia (odds ratio (OR) 4, 95% confidence interval (CI) 1.4&#x02013;13, p&#x000a0;=&#x000a0;0.01) and RVSP &#x02265;50&#x000a0;mmHg (OR 4.2, 95% CI 1.5&#x02013;13, p&#x000a0;=&#x000a0;0.01) (<xref rid="fig4" ref-type="fig">Fig. 4</xref>A). Hospital admission for heart failure was associated with pre-eclampsia (OR 5.7, 95% CI 1.6&#x02013;22, p&#x000a0;&#x0003c;&#x000a0;0.01), LVEF &#x02264;45% (OR 5.9, 95% CI 1.5&#x02013;26, p&#x000a0;=&#x000a0;0.01), pre-existing maternal diabetes (OR 5.7, 95% CI 1.7&#x02013;21, p&#x000a0;&#x0003c;&#x000a0;0.01) and pre-existing systemic hypertension (OR 5.5, 95% CI 1.8&#x02013;19, p&#x000a0;&#x0003c;&#x000a0;0.01) (<xref rid="fig4" ref-type="fig">Fig. 4</xref>B). While these clinical variables were associated with increased incidence of MACE and heart failure, 9 (38%) of the 24 women who experienced MACE had an RVSP &#x0003c;50&#x000a0;mmHg (<xref rid="fig2" ref-type="fig">Figs. 2</xref>A) and 12 (60%) of the 20 women with heart failure had normal LV systolic function.<table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>Description of maternal deaths in women with pulmonary hypertension.</p></caption><alt-text id="alttext0040">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Patient</th><th>Patient 1</th><th>Patient 2</th><th>Patient 3</th></tr></thead><tbody><tr><td align="left">Etiology of Group 2&#x000a0;PH</td><td align="left">ICM</td><td align="left">DCM</td><td align="left">HCM, LVOT obstruction</td></tr><tr><td align="left">Maternal race</td><td align="left">Non-Hispanic Black</td><td align="left">Non-Hispanic Black</td><td align="left">Non-Hispanic White</td></tr><tr><td align="left">LVEF (%)</td><td align="left">25</td><td align="left">25</td><td align="left">70</td></tr><tr><td align="left">RVSP (mmHg)</td><td align="left">47</td><td align="left">39</td><td align="left">43</td></tr><tr><td align="left">RV function</td><td align="left">normal</td><td align="left">normal</td><td align="left">normal</td></tr><tr><td align="left">Mean PAP (mmHg)</td><td align="left">&#x02013;</td><td align="left">43</td><td align="left">&#x02013;</td></tr><tr><td align="left">Timing of PH diagnosis</td><td align="left">Pre-pregnancy</td><td align="left">Pre-pregnancy</td><td align="left">Antepartum</td></tr><tr><td align="left">Cardio-obstetrics clinic care</td><td align="left">No</td><td align="left">Yes</td><td align="left">No</td></tr><tr><td align="left">Gestational age</td><td align="left">Miscarriage at 13 weeks</td><td align="left">38 weeks</td><td align="left">38 weeks</td></tr><tr><td align="left">Timing of post-partum death</td><td align="left">90 days</td><td align="left">11 months</td><td align="left">10 months</td></tr><tr><td align="left">Cause of death</td><td align="left">Unknown</td><td align="left">MSOF</td><td align="left">Unknown</td></tr><tr><td align="left">Clinical history</td><td align="left">CAD with prior PCI. Admitted for dilation and curettage after SAB.</td><td align="left">Pre-eclampsia before CD delivery. Multiple post-partum HF admissions.</td><td align="left">No prenatal care or follow up. Delivered precipitously on admission.</td></tr></tbody></table><table-wrap-foot><fn><p>PH indicates pulmonary hypertension; ICM, ischemic cardiomyopathy; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LVOT, left ventricular outflow tract; LVEF, left ventricular ejection fraction; RVSP, right ventricular systolic pressure; RV, right ventricle; PAP, pulmonary artery pressure; CAD; coronary artery disease; PCI, percutaneous coronary intervention; SAB, spontaneous abortion; MSOF, multisystem organ failure; CD, cesarean delivery; HF, heart failure.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl3"><label>Table 3</label><caption><p>Maternal and fetal outcomes of pregnant women with pulmonary hypertension.</p></caption><alt-text id="alttext0045">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th/><th>All Patients (n&#x000a0;=&#x000a0;70)<xref rid="tbl3fna" ref-type="table-fn">a</xref></th><th>Group 1&#x000a0;PH (n&#x000a0;=&#x000a0;12)<xref rid="tbl3fnb" ref-type="table-fn">b</xref></th><th>Group 2&#x000a0;PH (n&#x000a0;=&#x000a0;45)<xref rid="tbl3fnc" ref-type="table-fn">c</xref></th><th>Group 3&#x000a0;PH (n&#x000a0;=&#x000a0;4)<xref rid="tbl3n1" ref-type="table-fn">d</xref></th><th>Group 5&#x000a0;PH (n&#x000a0;=&#x000a0;9)</th><th>p-value (all PH Groups)</th><th>p-value (Group 1&#x000a0;PH vs Group 2&#x000a0;PH)</th></tr></thead><tbody><tr><td colspan="8" align="left">Cardiac Outcomes, n (%)</td></tr><tr><td colspan="8" align="left">Maternal death</td></tr><tr><td align="left">&#x000a0;In pregnancy</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">&#x000a0;42 days post-partum</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">&#x000a0;90 days post-partum</td><td align="left">1 (1.4)</td><td align="left">0 (0)</td><td align="left">1 (2.3)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0.96</td><td align="left">1</td></tr><tr><td align="left">&#x000a0;6 months post-partum</td><td align="left">1 (1.4)</td><td align="left">0 (0)</td><td align="left">1 (2.3)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0.96</td><td align="left">1</td></tr><tr><td align="left">&#x000a0;1-year post-partum</td><td align="left">3 (4.3)</td><td align="left">0 (0)</td><td align="left">3 (6.7)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0.73</td><td align="left">0.85</td></tr><tr><td align="left">MACE</td><td align="left">33 (37)</td><td align="left">5 (42)</td><td align="left">25 (40)</td><td align="left">0 (0)</td><td align="left">3 (33)</td><td align="left">0.42</td><td align="left">1</td></tr><tr><td align="left">&#x000a0;Thromboembolism</td><td align="left">6 (9)</td><td align="left">1 (8)</td><td align="left">2 (4)</td><td align="left">0 (0)</td><td align="left">3 (33)</td><td align="left">0.04</td><td align="left">1</td></tr><tr><td align="left">&#x000a0;Heart failure</td><td align="left">24 (29)</td><td align="left">3 (25)</td><td align="left">21 (38)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0.07</td><td align="left">0.83</td></tr><tr><td align="left">&#x000a0;Valvular intervention</td><td align="left">2 (3)</td><td align="left">1 (8)</td><td align="left">1 (2)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">NA</td><td align="left">1</td></tr><tr><td align="left">&#x000a0;Myocardial infarction</td><td align="left">1 (1.4)</td><td align="left">0 (0)</td><td align="left">1 (2)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">NA</td><td align="left">1</td></tr><tr><td align="left">&#x000a0;Arrhythmia</td><td align="left">5 (7)</td><td align="left">1 (9)</td><td align="left">2 (4)</td><td align="left">0 (0)</td><td align="left">2 (22)</td><td align="left">0.56</td><td align="left">1</td></tr><tr><td colspan="8" align="left">Obstetric Outcomes, n (%)</td></tr><tr><td align="left">Pre-eclampsia</td><td align="left">20 (29)</td><td align="left">2 (18)</td><td align="left">16 (36)</td><td align="left">0 (0)</td><td align="left">2 (22)</td><td align="left">0.41</td><td align="left">0.9</td></tr><tr><td align="left">Cesarean delivery</td><td align="left">38 (58)</td><td align="left">8 (73)</td><td align="left">23 (55)</td><td align="left">1 (25)</td><td align="left">6 (67)</td><td align="left">0.21</td><td align="left">0.4</td></tr><tr><td align="left">Post-partum hemorrhage</td><td align="left">10 (14)</td><td align="left">2 (20)</td><td align="left">6 (13)</td><td align="left">0 (0)</td><td align="left">2 (22)</td><td align="left">0.76</td><td align="left">0.95</td></tr><tr><td align="left">&#x000a0;EBL VD (mL)</td><td align="left">728 (836)</td><td align="left">400 (0)</td><td align="left">314 (90)</td><td align="left">300 (0)</td><td align="left">383 (57)</td><td align="left">0.41</td><td align="left">NA</td></tr><tr><td align="left">&#x000a0;EBL CD (mL)</td><td align="left">968 (949)</td><td align="left">1313 (1635)</td><td align="left">850 (792)</td><td align="left">800 (0)</td><td align="left">841 (220)</td><td align="left">0.89</td><td align="left">0.3</td></tr><tr><td colspan="8" align="left">Fetal Outcomes, n (%)</td></tr><tr><td align="left">Miscarriage</td><td align="left">4 (6)</td><td align="left">1 (8)</td><td align="left">3 (7)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0.74</td><td align="left">1</td></tr><tr><td align="left">Stillbirth</td><td align="left">1 (1.5)</td><td align="left">0 (0)</td><td align="left">1 (2.4)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0.96</td><td align="left">&#x0003c;0.01</td></tr><tr><td align="left">Preterm delivery</td><td align="left">32 (49)</td><td align="left">4 (36)</td><td align="left">24 (59)</td><td align="left">1 (33)</td><td align="left">3 (33)</td><td align="left">0.26</td><td align="left">0.33</td></tr><tr><td align="left">&#x000a0;Extremely preterm</td><td align="left">1 (3)</td><td align="left">0 (0)</td><td align="left">2 (8)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">&#x000a0;Very preterm</td><td align="left">10 (31)</td><td align="left">1 (25)</td><td align="left">7 (29)</td><td align="left">1 (100)</td><td align="left">3 (100)</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">&#x000a0;Late preterm</td><td align="left">21 (67)</td><td align="left">3 (75)</td><td align="left">16 (67)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">Gestational age (weeks)</td><td align="left">35 (3)</td><td align="left">36 (3)</td><td align="left">34 (4)</td><td align="left">34 (6)</td><td align="left">36 (4)</td><td align="left">0.55</td><td align="left">0.3</td></tr><tr><td align="left">Twin gestation</td><td align="left">2 (3)</td><td align="left">0 (0)</td><td align="left">2 (5)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0.87</td><td align="left">1</td></tr><tr><td align="left">Low birth weight</td><td align="left">27 (45)</td><td align="left">3 (27)</td><td align="left">19 (46)</td><td align="left">2 (67)</td><td align="left">3 (33)</td><td align="left">0.38</td><td align="left">1</td></tr><tr><td align="left">Neonatal mortality</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">0 (0)</td><td align="left">NA</td><td align="left">NA</td></tr></tbody></table><table-wrap-foot><fn><p>Continuous variables are presented as mean (standard deviation). PH indicates pulmonary hypertension; CD, cesarean delivery; VD, vaginal delivery; EBL, estimated blood loss; mL, milliliters; MACE, major adverse cardiac events, defined as maternal death during pregnancy or up to 42 days post-partum; hospital admission for decompensated heart failure requiring either intravenous diuretics, inotropes or mechanical circulatory support; myocardial infarction; thromboembolic events; sustained (&#x0003e;30&#x000a0;s) ventricular arrhythmias; cardiac transplant; or need for invasive cardiac intervention (valve replacement or coronary intervention).</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fna"><label>a</label><p id="ntpara0025">Unknown in all PH patients: MACE, n&#x000a0;=&#x000a0;2; thromboembolism, n&#x000a0;=&#x000a0;2; heart failure, n&#x000a0;=&#x000a0;2; arrhythmia, n&#x000a0;=&#x000a0;2; post-partum hemorrhage, n&#x000a0;=&#x000a0;5; gestational age, n&#x000a0;=&#x000a0;1; twin gestation, n&#x000a0;=&#x000a0;1; birth weight, n&#x000a0;=&#x000a0;6; miscarriage, n&#x000a0;=&#x000a0;2; fetal mortality, n&#x000a0;=&#x000a0;1; neonatal mortality, n&#x000a0;=&#x000a0;6.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnb"><label>b</label><p id="ntpara0030">Unknown in Group 1&#x000a0;PH: thromboembolism, n&#x000a0;=&#x000a0;1; heart failure, n&#x000a0;=&#x000a0;1; MACE, n&#x000a0;=&#x000a0;1; arrhythmia, n&#x000a0;=&#x000a0;1; post-partum hemorrhage, n&#x000a0;=&#x000a0;2; birth weight, n&#x000a0;=&#x000a0;4; neonatal mortality, n&#x000a0;=&#x000a0;1.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3fnc"><label>c</label><p id="ntpara0035">Unknown in Group 2&#x000a0;PH: MACE, n&#x000a0;=&#x000a0;1; thromboembolism, n&#x000a0;=&#x000a0;1; heart failure, n&#x000a0;=&#x000a0;1; arrhythmia, n&#x000a0;=&#x000a0;1; post-partum hemorrhage, n&#x000a0;=&#x000a0;1; gestational age, n&#x000a0;=&#x000a0;1; twin gestation, n&#x000a0;=&#x000a0;1; birth weight, n&#x000a0;=&#x000a0;1; miscarriage, n&#x000a0;=&#x000a0;1; neonatal mortality, n&#x000a0;=&#x000a0;4.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl3n1"><label>d</label><p id="ntparaHgd9ZfMwbu">Unknown in Group 3 PH: post-partum hemorrhage, n = 2; birth weight, n = 1; miscarriage, n = 1; fetal mortality, n = 1; neonatal mortality, n = 1.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl4"><label>Table 4</label><caption><p>Summary of major adverse cardiac events in pregnant women with pulmonary hypertension.</p></caption><alt-text id="alttext0050">Table 4</alt-text><table frame="hsides" rules="groups"><tbody><tr><td align="left"><bold><underline>Decompensated heart failure admissions</underline>: 24 events in 20 women.</bold></td></tr><tr><td align="left"><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0160">Intravenous diuretics: 21 admissions in 16 women (2 women were admitted 3 times each)</p></list-item></list></td></tr><tr><td align="left"><list list-type="simple" id="ulist0015"><list-item id="u0015"><label>&#x02022;</label><p id="p0165">Inotropes: 2</p></list-item></list></td></tr><tr><td align="left"><list list-type="simple" id="ulist0020"><list-item id="u0020"><label>&#x02022;</label><p id="p0170">Inotropes and mechanical support: 1 (post-partum intra-aortic balloon pump, eventually LVAD)</p></list-item></list></td></tr><tr><td align="left"><bold><underline>Valvular interventions</underline>: 2 interventions in 2 women.</bold></td></tr><tr><td align="left"><list list-type="simple" id="ulist0025"><list-item id="u0025"><label>&#x02022;</label><p id="p0175">ToF/PA, unrepaired VSD, ES with RV to PA conduit stenosis underwent TPVR (21&#x000a0;weeks&#x000a0;GA)<xref rid="tbl4fna" ref-type="table-fn">a</xref></p></list-item></list></td></tr><tr><td align="left"><list list-type="simple" id="ulist0030"><list-item id="u0030"><label>&#x02022;</label><p id="p0180">Mitral valve thrombosis requiring emergent CD followed by redo MVR (26&#x000a0;weeks&#x000a0;GA)</p></list-item></list></td></tr><tr><td align="left"><bold><underline>Thromboembolism</underline>: 6 events in 6 women.</bold></td></tr><tr><td align="left"><list list-type="simple" id="ulist0035"><list-item id="u0035"><label>&#x02022;</label><p id="p0185">Mechanical mitral valve thrombosis: 1</p></list-item></list></td></tr><tr><td align="left"><list list-type="simple" id="ulist0040"><list-item id="u0040"><label>&#x02022;</label><p id="p0190">Pulmonary embolism: 3</p></list-item></list></td></tr><tr><td align="left"><list list-type="simple" id="ulist0045"><list-item id="u0045"><label>&#x02022;</label><p id="p0195">Deep venous thrombosis and pulmonary embolism: 1</p></list-item></list></td></tr><tr><td align="left"><list list-type="simple" id="ulist0050"><list-item id="u0050"><label>&#x02022;</label><p id="p0200">Catheter associated right atrial thrombus: 1</p></list-item></list></td></tr><tr><td align="left"><bold><underline>Myocardial infarction</underline>: 1 event in 1 woman.</bold></td></tr><tr><td align="left"><list list-type="simple" id="ulist0055"><list-item id="u0055"><label>&#x02022;</label><p id="p0205">Spontaneous coronary artery dissection (37&#x000a0;weeks&#x000a0;GA)</p></list-item></list></td></tr><tr><td align="left"><bold><underline>Total MACE</underline>: 33 major adverse cardiac events (MACE) in 26 women</bold><xref rid="tbl4fnb" ref-type="table-fn">b</xref></td></tr></tbody></table><table-wrap-foot><fn><p>LVAD indicates left ventricular assist device; ToF/PA, Tetralogy of Fallot with pulmonary atresia; VSD, ventricular septal defect; ES, Eisenmenger syndrome; RV, right ventricle; PA, pulmonary artery; TPVR, transcatheter pulmonary valve replacement; GA, gestational age; CD, cesarean delivery; MVR, mitral valve replacement.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl4fna"><label>a</label><p id="ntpara0040">Patient had elevated pulmonary vascular resistance in addition to RV-PA conduit stenosis and was treated with IV prostacyclin.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl4fnb"><label>b</label><p id="ntpara0045">There were 2 women in Group 2&#x000a0;PH with events in multiple categories: the first with a mechanical mitral valve thrombosis leading to heart failure and urgent valve replacement, the second with both a pulmonary embolism and heart failure.</p></fn></table-wrap-foot></table-wrap><fig id="fig3"><label>Fig. 3</label><caption><p>Maternal and fetal outcomes in pregnant women with pulmonary hypertension (PH). Maternal cardiac (top), obstetric (middle) and fetal (bottom) outcomes for <bold>(A)</bold> all women with PH (n&#x000a0;=&#x000a0;70) and <bold>(B)</bold> and women with Group 2&#x000a0;PH (n&#x000a0;=&#x000a0;45). Outcomes in Group 2&#x000a0;PH subgroups are reported due to heterogeneity of this PH group, however statistical analysis was not performed due to small sample size. HFrEF indicates heart failure with reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HCM, hypertrophic cardiomyopathy. * Other etiologies for Group 2&#x000a0;PH included: non-compaction cardiomyopathy (n&#x000a0;=&#x000a0;1), high output heart failure (n&#x000a0;=&#x000a0;2) and women with 2 or more cardiac risk factors for left heart disease as outlined by the World Society of Pulmonary Hypertension (n&#x000a0;=&#x000a0;9). &#x02020; Myocardial infarction was due to spontaneous coronary artery dissection.</p></caption><alt-text id="alttext0025">Fig. 3</alt-text><graphic xlink:href="gr3"/></fig><fig id="fig4"><label>Fig. 4</label><caption><p>Univariate analysis for clinical variables associated with <bold>(A)</bold> major adverse cardiac events (MACE) and <bold>(B)</bold> hospital admission for decompensated heart failure in pregnant women with pulmonary hypertension. Clinical variables associated with MACE included pre-eclampsia (p&#x000a0;=&#x000a0;0.01) and right ventricular systolic pressure (RVSP)&#x000a0;&#x02265;&#x000a0;50&#x000a0;mmHg (p&#x000a0;=&#x000a0;0.01). Hospital admission for decompensated heart failure was associated with pre-eclampsia (p&#x000a0;&#x0003c;&#x000a0;0.01), left ventricular ejection fraction (LVEF)&#x000a0;&#x02264;&#x000a0;45% (p&#x000a0;=&#x000a0;0.01), pre-existing maternal diabetes (p&#x000a0;&#x0003c;&#x000a0;0.01), and pre-existing maternal systemic hypertension (p&#x000a0;&#x0003c;&#x000a0;0.01). OR indicates odds ratio; CI, confidence interval; RV, right ventricle.</p></caption><alt-text id="alttext0030">Fig. 4</alt-text><graphic xlink:href="gr4"/></fig></p></sec><sec id="sec3.3"><label>3.3</label><title>Delivery mode and obstetric outcomes</title><p id="p0065">CD was performed in 38 (58%) women, with 7 (18%) women requiring an emergent CD; however, only 1 (3%) woman required an emergent CD for a cardiac indication (mechanical mitral valve thrombosis). Post-partum hemorrhage occurred in 10 (14%) women, of whom only 2 (20%) were on anticoagulation. Two women with Eisenmenger Syndrome (Group 1&#x000a0;PH) and 1 with Group 2&#x000a0;PH underwent CD complicated by post-operative hemorrhage requiring exploratory laparotomy. Pre-eclampsia occurred in 20 (29%) women from this cohort. Overall, CD, post-partum hemorrhage and pre-eclampsia were similar across WHO PH subgroups (details described in <xref rid="tbl3" ref-type="table">Table 3</xref> and <xref rid="fig3" ref-type="fig">Fig. 3</xref>A/B, <xref rid="appsec1" ref-type="sec">Table S6</xref> and <xref rid="appsec1" ref-type="sec">Table S7</xref>).</p></sec><sec id="sec3.4"><label>3.4</label><title>Fetal outcomes</title><p id="p0070">There was 1 (1.5%) stillbirth in this cohort with multiple fetal anomalies, but there were no neonatal deaths. In completed pregnancies, the mean gestational age at delivery was 35&#x000a0;&#x000b1;&#x000a0;3 weeks. Preterm delivery occurred in 32 (49%), and was similar across WHO PH subgroups. Fetal outcomes are described in <xref rid="tbl3" ref-type="table">Table 3</xref> and <xref rid="fig3" ref-type="fig">Fig. 3</xref>A/B.</p></sec><sec id="sec3.5"><label>3.5</label><title>Overall outcome</title><p id="p0075">In women with complete follow-up information (n&#x000a0;=&#x000a0;65, 93%), only 24 (37%) completed a viable pregnancy (gestational age &#x0003e;10 weeks) free of MACE, pre-eclampsia, post-partum hemorrhage, stillbirth and extreme or very preterm birth. Finally, while maternal race differed between PH groups (<xref rid="tbl1" ref-type="table">Table 1</xref>), there was no association between maternal race and MACE, mortality, preterm birth, birth weight, pre-eclampsia or post-partum hemorrhage (<xref rid="appsec1" ref-type="sec">Table S8</xref>).</p></sec></sec><sec id="sec4"><label>4</label><title>Discussion</title><p id="p0080">In this large cohort of pregnant women with PH, we demonstrate that women with WHO Group 2&#x000a0;PH have significant morbidity and mortality, similar to the rates experienced by women with WHO Group 1&#x000a0;PH in prior studies [<xref rid="bib9" ref-type="bibr">9</xref>,<xref rid="bib18" ref-type="bibr">18</xref>]. In addition, adverse cardiac, obstetric and fetal event rates for women with Group 2&#x000a0;PH were similar to Group 1&#x000a0;PH. There was significant morbidity in all PH groups, as only 37% of women completed a viable pregnancy without a significant maternal or fetal event. We found that pre-eclampsia and RVSP &#x02265;50&#x000a0;mmHg were associated with increased rates of MACE, and that LV dysfunction, pre-existing systemic hypertension, diabetes and pre-eclampsia were associated with heart failure in pregnant women with PH.</p><p id="p0085">Pregnancy related outcomes for women with Group 2&#x000a0;PH are not well described [<xref rid="bib19" ref-type="bibr">19</xref>], as much of the previous literature has focused on women with Group 1&#x000a0;PH [<xref rid="bib4" ref-type="bibr">4</xref>,<xref rid="bib8" ref-type="bibr">8</xref>,<xref rid="bib9" ref-type="bibr">9</xref>]. Prior studies that included Group 2&#x000a0;PH were comprised of a high prevalence of valvular heart disease leading to PH, and reported lower mortality than Group 1&#x000a0;PH [<xref rid="bib9" ref-type="bibr">9</xref>,<xref rid="bib18" ref-type="bibr">18</xref>,<xref rid="bib20" ref-type="bibr">20</xref>]. In comparison, our study reports late mortality in Group 2&#x000a0;PH, and though sample size is limited (n&#x000a0;=&#x000a0;12), 100% 1-year survival in women with Group 1&#x000a0;PH. We hypothesize this may be because the majority of women in this Group 1&#x000a0;PH cohort were diagnosed before pregnancy, thereby facilitating early and up-front therapy, whereas the use of prostacyclin therapy was variable in prior studies [<xref rid="bib4" ref-type="bibr">4</xref>,<xref rid="bib8" ref-type="bibr">8</xref>,<xref rid="bib9" ref-type="bibr">9</xref>,<xref rid="bib18" ref-type="bibr">18</xref>]. Therefore, similar to prior case series [<xref rid="bib21" ref-type="bibr">21</xref>], outcomes may be better than what has previously been reported. In women with Group 2&#x000a0;PH, two of the women who died had LV systolic dysfunction, which is known to be a risk factor for poor pregnancy outcomes [<xref rid="bib22" ref-type="bibr">22</xref>]. The natural history of cardiomyopathy can be worsened by the hemodynamic changes in pregnancy [<xref rid="bib23" ref-type="bibr">23</xref>], and likely contributed to the death of at least 1 of the women, who had multiple heart failure hospitalizations post-partum. Finally, we may have identified more deaths in Group 2&#x000a0;PH due to longer follow up than prior reports [<xref rid="bib9" ref-type="bibr">9</xref>,<xref rid="bib18" ref-type="bibr">18</xref>,<xref rid="bib20" ref-type="bibr">20</xref>,<xref rid="bib24" ref-type="bibr">24</xref>]. Given that pregnancy alters long term cardiovascular risk [<xref rid="bib25" ref-type="bibr">25</xref>], and the majority of deaths within 1 year of pregnancy are related to cardiovascular disease [<xref rid="bib5" ref-type="bibr">5</xref>], extended follow-up in PH patients may be warranted to evaluate late post-partum mortality.</p><p id="p0090">In this study we also report significant morbidity, with similar rates of MACE in Groups 1 and 2&#x000a0;PH. In Group 2&#x000a0;PH, 17 (38%) women were hospitalized for heart failure, including women that required multiple admissions, inotropes and mechanical circulatory support. The underlying heterogeneity in Group 2&#x000a0;PH makes the broad assessment of outcomes challenging, however it is notable that adverse events occurred even in women with normal LV systolic function. RVSP &#x02265;50&#x000a0;mmHg was associated with increased risk of MACE regardless of WHO PH subgroup; however, 9 (38%) of the 24 women who experienced adverse events had a lower RVSP, and most of those women (n&#x000a0;=&#x000a0;8) were in Group 2&#x000a0;PH (<xref rid="fig2" ref-type="fig">Fig. 2</xref>A). This suggests that even mildly elevated pulmonary pressures in pregnancy, especially in Group 2&#x000a0;PH, may increase the risk of adverse outcomes. While MACE occurred across all etiologies for Group 2&#x000a0;PH, 44% of MACE in Group 2&#x000a0;PH occurred in women with LV systolic dysfunction. Most of the women with LV systolic dysfunction who experienced MACE were diagnosed in late pregnancy (<xref rid="appsec1" ref-type="sec">Table S2</xref>), highlighting the challenges of preventing adverse events and limitations of preconception counseling in this population. Other risk factors associated with admission for heart failure, including systemic hypertension and diabetes, were more common in Group 2&#x000a0;PH. Pre-existing hypertension and diabetes are thought to impair endothelial function and alter the normal hemodynamic adaptations to pregnancy, potentially leading to pre-eclampsia [<xref rid="bib26" ref-type="bibr">26</xref>]. This may have increased the prevalence of pre-eclampsia (29%) in our cohort compared to prior reports [<xref rid="bib7" ref-type="bibr">7</xref>,<xref rid="bib18" ref-type="bibr">18</xref>], and contributed to the incidence of heart failure, as women with pre-eclampsia have increased RVSP, diastolic dysfunction and peripartum pulmonary edema [<xref rid="bib27" ref-type="bibr">27</xref>]. Identification of these traditional cardiovascular disease risk factors in women with elevated RVSP requires further study to determine if it prospectively may assist in determining the risk for decompensated heart failure during pregnancy. While mortality in Group 1&#x000a0;PH was lower compared to other studies, significant maternal morbidity was noted, as 25% of patients required treatment for heart failure, and 2 patients with Eisenmenger syndrome had complications, including transcatheter pulmonary valve replacement during pregnancy and significant post-partum hemorrhage.</p><p id="p0095">We found significant non-cardiac morbidity in this population, including high rates of CD, post-partum hemorrhage, and preterm delivery: These findings are important for counseling of patients with PH considering pregnancy. The rate of CD in this cohort (58%) was higher than local reports (31%) [<xref rid="bib28" ref-type="bibr">28</xref>], with the emergent CD rate (18%) more than double our institution's emergent CD rate (8%; institutional data). Despite the overall high CD rate in this cohort, our results are similar to prior studies and may be related to guideline recommendations [<xref rid="bib9" ref-type="bibr">9</xref>,<xref rid="bib18" ref-type="bibr">18</xref>,<xref rid="bib19" ref-type="bibr">19</xref>], and the majority of emergent CD were performed for non-reassuring fetal wellbeing (<xref rid="appsec1" ref-type="sec">Table S6</xref>). Additionally, we report an increased rate of post-partum hemorrhage (10%) compared to previous cohorts of women with PH [<xref rid="bib18" ref-type="bibr">18</xref>,<xref rid="bib24" ref-type="bibr">24</xref>]. Post-partum hemorrhage is not unexpected in patients with Eisenmenger syndrome [<xref rid="bib29" ref-type="bibr">29</xref>]; however, the increased rates of hemorrhage in other etiologies of PH may warrant further study.</p><sec id="sec4.1"><label>4.1</label><title>Limitations</title><p id="p0100">We recognize this data has limitations. Though only women with intermediate to high probability of PH by echocardiogram were included, identification of PH by echocardiogram may have led to over-diagnosis of PH; this may have resulted in underestimation of the overall proportion of patients in Groups 2, 3 and 5&#x000a0;PH with adverse events. Group 1&#x000a0;PH outcomes are from a single PH and maternal fetal medicine referral center, thus may not be generalizable to all institutions. Furthermore, dedicated cardio-obstetrics team care would be the standard for all patients in the current era [<xref rid="bib30" ref-type="bibr">30</xref>,<xref rid="bib31" ref-type="bibr">31</xref>], therefore outcomes on Group 2&#x000a0;PH may be improved with appropriate medical therapy and ongoing follow up. While the overall sample size is similar to previously published reports of pregnant women with PH, interpretation of WHO PH subgroup outcomes should be done cautiously, and sample size did not allow for identification of risk factors for MACE in individual PH subgroups. The study is retrospective; therefore, variables associated with outcomes do not indicate causation. Challenges differentiating pre-eclampsia from pre-existing systemic hypertension could have led to increased diagnosis of pre-eclampsia by the treating clinicians, over-estimating its effect size in relation to MACE and heart failure. In addition, pre-pregnancy New York Heart Association functional class was not available in the majority of patients, therefore this was not assessed for association with MACE. We investigated limited neonatal outcomes, and pregnancies with multiple gestations were included, increasing the heterogeneity in fetal outcomes. TTE data was based on the report in the medical record, thus subject to inter-reader variability. Finally, there was missing data on a small portion of patients.</p></sec></sec><sec id="sec5"><label>5</label><title>Conclusions</title><p id="p0105">Pregnancy in women with Group 2&#x000a0;PH is often felt to be lower risk than Group 1&#x000a0;PH, however our data support similar rates of MACE and heart failure to Group 1&#x000a0;PH. Furthermore, late post-partum mortality in Group 2&#x000a0;PH was higher than Group 1&#x000a0;PH, which has not been previously described. MACE was associated with RVSP &#x02265;50&#x000a0;mmHg and pre-eclampsia, whereas admission for decompensated heart failure was associated with LV dysfunction, pre-existing systemic hypertension, diabetes and pre-eclampsia. Finally, there was significant morbidity in all PH groups, as only 37% of women completed a viable pregnancy without a significant maternal or fetal event. Prospective studies with an extended post-partum observation period are needed to further stratify the true risk for pregnant women with Group 2&#x000a0;PH.</p></sec><sec sec-type="data-availability" id="sec6"><title>Data availability</title><p id="p0110">Data is available upon reasonable request and agreement of the coauthors.</p></sec><sec id="sec7"><title>Authors&#x02019; contributions</title><p id="p0115">The authors take responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation. Concept/design: SR, WHM; Data collection: WHM, SG: Drafting and writing of article: WHM, SR, SG, EAB; Data analysis/interpretation: WHM, SR, WL, SG; Critical revision and approval of the article: WHM, SG, WL, LTL, MC, RLB, CJD, EAB, SR.</p></sec><sec id="sec8"><title>Sources of funding</title><p id="p0120">The authors (EAB and RLB) are supported by <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/100000002</institution-id><institution>NIH</institution></institution-wrap></funding-source> grants: <award-id award-type="grant" rid="gs1">K08HL148701</award-id> (EAB), <award-id award-type="grant" rid="gs1">1R01HL134673-02</award-id> (RLB).</p></sec><sec sec-type="COI-statement"><title>Declaration of competing interest</title><p id="p0125">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Strange</surname><given-names>G.</given-names></name><name><surname>Playford</surname><given-names>D.</given-names></name><name><surname>Stewart</surname><given-names>S.</given-names></name><name><surname>Deague</surname><given-names>J.A.</given-names></name><name><surname>Nelson</surname><given-names>H.</given-names></name><name><surname>Kent</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort</article-title><source>Heart</source><volume>98</volume><year>2012</year><fpage>1805</fpage><lpage>1811</lpage><pub-id pub-id-type="pmid">22760869</pub-id>
</element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Simonneau</surname><given-names>G.</given-names></name><name><surname>Montani</surname><given-names>D.</given-names></name><name><surname>Celermajer</surname><given-names>D.S.</given-names></name><name><surname>Denton</surname><given-names>C.P.</given-names></name><name><surname>Gatzoulis</surname><given-names>M.A.</given-names></name><name><surname>Krowka</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Haemodynamic definitions and updated clinical classification of pulmonary hypertension</article-title><source>Eur Respir J</source><volume>53</volume><year>2019</year></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Regitz-Zagrosek</surname><given-names>V.</given-names></name><name><surname>Roos-Hesselink</surname><given-names>J.W.</given-names></name><name><surname>Bauersachs</surname><given-names>J.</given-names></name><name><surname>Blomstr&#x000f6;m-Lundqvist</surname><given-names>C.</given-names></name><name><surname>C&#x000ed;fkov&#x000e1;</surname><given-names>R.</given-names></name><name><surname>De Bonis</surname><given-names>M.</given-names></name><etal/></person-group><article-title>2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy</article-title><source>Eur Heart J</source><volume>39</volume><year>2018</year><fpage>3165</fpage><lpage>3241</lpage><pub-id pub-id-type="pmid">30165544</pub-id>
</element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>B.M.</given-names></name><name><surname>Zemp</surname><given-names>L.</given-names></name><name><surname>Seifert</surname><given-names>B.</given-names></name><name><surname>Hess</surname><given-names>O.M.</given-names></name></person-group><article-title>Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996</article-title><source>J Am Coll Cardiol</source><volume>31</volume><year>1998</year><fpage>1650</fpage><lpage>1657</lpage><pub-id pub-id-type="pmid">9626847</pub-id>
</element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Creanga</surname><given-names>A.A.</given-names></name><name><surname>Syverson</surname><given-names>C.</given-names></name><name><surname>Seed</surname><given-names>K.</given-names></name><name><surname>Callaghan</surname><given-names>W.M.</given-names></name></person-group><article-title>Pregnancy-related mortality in the United States, 2011-2013</article-title><source>Obstet Gynecol</source><volume>130</volume><year>2017</year><fpage>366</fpage><lpage>373</lpage><pub-id pub-id-type="pmid">28697109</pub-id>
</element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Elkayam</surname><given-names>U.</given-names></name><name><surname>Goland</surname><given-names>S.</given-names></name><name><surname>Pieper</surname><given-names>P.G.</given-names></name><name><surname>Silverside</surname><given-names>C.K.</given-names></name></person-group><article-title>High-risk cardiac disease in pregnancy: Part I</article-title><source>J Am Coll Cardiol</source><volume>68</volume><year>2016</year><fpage>396</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">27443437</pub-id>
</element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Lima</surname><given-names>F.V.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Stergiopoulos</surname><given-names>K.</given-names></name></person-group><article-title>National trends and in-hospital outcomes in pregnant women with heart disease in the United States</article-title><source>Am J Cardiol</source><volume>119</volume><year>2017</year><fpage>1694</fpage><lpage>1700</lpage><pub-id pub-id-type="pmid">28343597</pub-id>
</element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>B&#x000e9;dard</surname><given-names>E.</given-names></name><name><surname>Dimopoulos</surname><given-names>K.</given-names></name><name><surname>Gatzoulis</surname><given-names>M.A.</given-names></name></person-group><article-title>Has there been any progress made on pregnancy outcomes among women with pulmonary arterial hypertension?</article-title><source>Eur Heart J</source><volume>30</volume><year>2009</year><fpage>256</fpage><lpage>265</lpage><pub-id pub-id-type="pmid">19147605</pub-id>
</element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>M.L.</given-names></name><name><surname>Landau</surname><given-names>R.</given-names></name><name><surname>Viktorsdottir</surname><given-names>O.</given-names></name><name><surname>Banayan</surname><given-names>J.</given-names></name><name><surname>Grant</surname><given-names>T.</given-names></name><name><surname>Bateman</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Pulmonary hypertension in pregnancy: a report of 49 cases at four tertiary north American sites</article-title><source>Obstet Gynecol</source><volume>129</volume><year>2017</year><fpage>511</fpage><lpage>520</lpage><pub-id pub-id-type="pmid">28178055</pub-id>
</element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Duarte</surname><given-names>A.G.</given-names></name><name><surname>Thomas</surname><given-names>S.</given-names></name><name><surname>Safdar</surname><given-names>Z.</given-names></name><name><surname>Torres</surname><given-names>F.</given-names></name><name><surname>Pacheco</surname><given-names>L.D.</given-names></name><name><surname>Feldman</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Management of pulmonary arterial hypertension during pregnancy: a retrospective, multicenter experience</article-title><source>Chest</source><volume>143</volume><year>2013</year><fpage>1330</fpage><lpage>1336</lpage><pub-id pub-id-type="pmid">23100080</pub-id>
</element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Gali&#x000e8;</surname><given-names>N.</given-names></name><name><surname>Humbert</surname><given-names>M.</given-names></name><name><surname>Vachiery</surname><given-names>J.L.</given-names></name><name><surname>Gibbs</surname><given-names>S.</given-names></name><name><surname>Lang</surname><given-names>I.</given-names></name><name><surname>Torbicki</surname><given-names>A.</given-names></name><etal/></person-group><article-title>2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European society of cardiology (ESC) and the European respiratory society (ERS): endorsed by: association for European paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT)</article-title><source>Eur Heart J</source><volume>37</volume><year>2016</year><fpage>67</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">26320113</pub-id>
</element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Strange</surname><given-names>G.</given-names></name><name><surname>Stewart</surname><given-names>S.</given-names></name><name><surname>Celermajer</surname><given-names>D.S.</given-names></name><name><surname>Prior</surname><given-names>D.</given-names></name><name><surname>Scalia</surname><given-names>G.M.</given-names></name><name><surname>Marwick</surname><given-names>T.H.</given-names></name><etal/></person-group><article-title>Threshold of pulmonary hypertension associated with increased mortality</article-title><source>J Am Coll Cardiol</source><volume>73</volume><year>2019</year><fpage>2660</fpage><lpage>2672</lpage><pub-id pub-id-type="pmid">31146810</pub-id>
</element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Vachi&#x000e9;ry</surname><given-names>J.L.</given-names></name><name><surname>Tedford</surname><given-names>R.J.</given-names></name><name><surname>Rosenkranz</surname><given-names>S.</given-names></name><name><surname>Palazzini</surname><given-names>M.</given-names></name><name><surname>Lang</surname><given-names>I.</given-names></name><name><surname>Guazzi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Pulmonary hypertension due to left heart disease</article-title><source>Eur Respir J</source><volume>53</volume><year>2019</year></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Nathan</surname><given-names>S.D.</given-names></name><name><surname>Barbera</surname><given-names>J.A.</given-names></name><name><surname>Gaine</surname><given-names>S.P.</given-names></name><name><surname>Harari</surname><given-names>S.</given-names></name><name><surname>Martinez</surname><given-names>F.J.</given-names></name><name><surname>Olschewski</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Pulmonary hypertension in chronic lung disease and hypoxia</article-title><source>Eur Respir J</source><volume>53</volume><year>2019</year></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="book" id="sref15"><source>Trends in maternal mortality 2000 to 2017: estimates by WHO, UNICEF, UNFPA, world bank group and the united nations population division</source><year>2019</year><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva</publisher-loc></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><collab>Bulletins-Obstetrics CoP</collab></person-group><article-title>Practice bulletin No. 183: postpartum hemorrhage</article-title><comment>e168-e186</comment><source>Obstet Gynecol</source><volume>130</volume><year>2017</year></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="book" id="sref17"><person-group person-group-type="author"><name><surname>H</surname><given-names>C.P.</given-names></name><name><surname>K</surname><given-names>M.V.</given-names></name><name><surname>Born Too Soon</surname><given-names>J.L.</given-names></name></person-group><part-title>The global action report on preterm birth. March of Dimes, PMNCH, Save the Children</part-title><year>2012</year><publisher-name>WHO</publisher-name></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Sliwa</surname><given-names>K.</given-names></name><name><surname>van Hagen</surname><given-names>I.M.</given-names></name><name><surname>Budts</surname><given-names>W.</given-names></name><name><surname>Swan</surname><given-names>L.</given-names></name><name><surname>Sinagra</surname><given-names>G.</given-names></name><name><surname>Caruana</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Pulmonary hypertension and pregnancy outcomes: data from the registry of pregnancy and cardiac disease (ROPAC) of the European society of cardiology</article-title><source>Eur J Heart Fail</source><volume>18</volume><year>2016</year><fpage>1119</fpage><lpage>1128</lpage><pub-id pub-id-type="pmid">27384461</pub-id>
</element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Hemnes</surname><given-names>A.R.</given-names></name><name><surname>Kiely</surname><given-names>D.G.</given-names></name><name><surname>Cockrill</surname><given-names>B.A.</given-names></name><name><surname>Safdar</surname><given-names>Z.</given-names></name><name><surname>Wilson</surname><given-names>V.J.</given-names></name><name><surname>Al Hazmi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Statement on pregnancy in pulmonary hypertension from the pulmonary vascular research institute</article-title><source>Pulm Circ</source><volume>5</volume><year>2015</year><fpage>435</fpage><lpage>465</lpage><pub-id pub-id-type="pmid">26401246</pub-id>
</element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X.</given-names></name><name><surname>Feng</surname><given-names>J.</given-names></name><name><surname>Shi</surname><given-names>J.</given-names></name></person-group><article-title>Pregnancy and pulmonary hypertension: an exploratory analysis of risk factors and outcomes</article-title><source>Medicine (Baltimore)</source><volume>97</volume><year>2018</year><object-id pub-id-type="publisher-id">e13035</object-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>J.S.</given-names></name><name><surname>Mueller</surname><given-names>J.</given-names></name><name><surname>Daniels</surname><given-names>C.J.</given-names></name></person-group><article-title>Pulmonary arterial hypertension in the setting of pregnancy: a case series and standard treatment approach</article-title><source>Lung</source><volume>190</volume><year>2012</year><fpage>155</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">22139549</pub-id>
</element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Silversides</surname><given-names>C.K.</given-names></name><name><surname>Grewal</surname><given-names>J.</given-names></name><name><surname>Mason</surname><given-names>J.</given-names></name><name><surname>Sermer</surname><given-names>M.</given-names></name><name><surname>Kiess</surname><given-names>M.</given-names></name><name><surname>Rychel</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Pregnancy outcomes in women with heart disease: the CARPREG II study</article-title><source>J Am Coll Cardiol</source><volume>71</volume><year>2018</year><fpage>2419</fpage><lpage>2430</lpage><pub-id pub-id-type="pmid">29793631</pub-id>
</element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Grewal</surname><given-names>J.</given-names></name><name><surname>Siu</surname><given-names>S.C.</given-names></name><name><surname>Ross</surname><given-names>H.J.</given-names></name><name><surname>Mason</surname><given-names>J.</given-names></name><name><surname>Balint</surname><given-names>O.H.</given-names></name><name><surname>Sermer</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Pregnancy outcomes in women with dilated cardiomyopathy</article-title><source>J Am Coll Cardiol</source><volume>55</volume><year>2009</year><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">20117363</pub-id>
</element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>E.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Lima</surname><given-names>F.V.</given-names></name><name><surname>Stergiopoulos</surname><given-names>K.</given-names></name></person-group><article-title>Pulmonary hypertension and pregnancy outcomes: insights from the national inpatient sample</article-title><source>J Am Heart Assoc</source><volume>6</volume><year>2017</year></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Ness</surname><given-names>R.B.</given-names></name><name><surname>Harris</surname><given-names>T.</given-names></name><name><surname>Cobb</surname><given-names>J.</given-names></name><name><surname>Flegal</surname><given-names>K.M.</given-names></name><name><surname>Kelsey</surname><given-names>J.L.</given-names></name><name><surname>Balanger</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Number of pregnancies and the subsequent risk of cardiovascular disease</article-title><source>N Engl J Med</source><volume>328</volume><year>1993</year><fpage>1528</fpage><lpage>1533</lpage><pub-id pub-id-type="pmid">8267704</pub-id>
</element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Hauspurg</surname><given-names>A.</given-names></name><name><surname>Ying</surname><given-names>W.</given-names></name><name><surname>Hubel</surname><given-names>C.A.</given-names></name><name><surname>Michos</surname><given-names>E.D.</given-names></name><name><surname>Ouyang</surname><given-names>P.</given-names></name></person-group><article-title>Adverse pregnancy outcomes and future maternal cardiovascular disease</article-title><source>Clin Cardiol</source><volume>41</volume><year>2018</year><fpage>239</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">29446836</pub-id>
</element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Vaught</surname><given-names>A.J.</given-names></name><name><surname>Kovell</surname><given-names>L.C.</given-names></name><name><surname>Szymanski</surname><given-names>L.M.</given-names></name><name><surname>Mayer</surname><given-names>S.A.</given-names></name><name><surname>Seifert</surname><given-names>S.M.</given-names></name><name><surname>Vaidya</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Acute cardiac effects of severe pre-eclampsia</article-title><source>J Am Coll Cardiol</source><volume>72</volume><year>2018</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">29957219</pub-id>
</element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="other" id="sref28"><person-group person-group-type="author"><name><surname>Center for Disease Control and Prevention</surname></name></person-group><article-title>National Health statistics</article-title><ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/nchs/pressroom/states/ohio/oh.htm" id="intref0015">https://www.cdc.gov/nchs/pressroom/states/ohio/oh.htm</ext-link></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Cauldwell</surname><given-names>M.</given-names></name><name><surname>Von Klemperer</surname><given-names>K.</given-names></name><name><surname>Uebing</surname><given-names>A.</given-names></name><name><surname>Swan</surname><given-names>L.</given-names></name><name><surname>Steer</surname><given-names>P.J.</given-names></name><name><surname>Gatzoulis</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Why is post-partum haemorrhage more common in women with congenital heart disease?</article-title><source>Int J Cardiol</source><volume>218</volume><year>2016</year><fpage>285</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">27240153</pub-id>
</element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>L.S.</given-names></name><name><surname>Warnes</surname><given-names>C.A.</given-names></name><name><surname>Bradley</surname><given-names>E.</given-names></name><name><surname>Burton</surname><given-names>T.</given-names></name><name><surname>Economy</surname><given-names>K.</given-names></name><name><surname>Mehran</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Cardiovascular considerations in caring for pregnant patients: a scientific statement from the American heart association</article-title><source>Circulation</source><year>2020</year><comment>CIR0000000000000772</comment></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Magun</surname><given-names>E.</given-names></name><name><surname>DeFilippis</surname><given-names>E.M.</given-names></name><name><surname>Noble</surname><given-names>S.</given-names></name><name><surname>LaSala</surname><given-names>A.</given-names></name><name><surname>Waksmonski</surname><given-names>C.</given-names></name><name><surname>D'Alton</surname><given-names>M.E.</given-names></name><etal/></person-group><article-title>Cardiovascular care for pregnant women with cardiovascular disease</article-title><source>J Am Coll Cardiol</source><volume>76</volume><year>2020</year><fpage>2102</fpage><lpage>2113</lpage><pub-id pub-id-type="pmid">33121718</pub-id>
</element-citation></ref></ref-list><sec id="appsec3" sec-type="supplementary-material"><title>Supplemental Materials</title><p id="p0155">Supplemental material with detailed methodology and <xref rid="appsec1" ref-type="sec">Supplemental Table 1&#x02013;8</xref>.</p></sec><sec id="appsec1" sec-type="supplementary-material"><label>Appendix A</label><title>Supplementary data</title><p id="p0145">The following is the Supplementary data to this article:<supplementary-material content-type="local-data" id="mmc1"><caption><title>Multimedia component 1</title></caption><media xlink:href="mmc1.docx"><alt-text>Multimedia component 1</alt-text></media></supplementary-material></p></sec><ack id="ack0010"><title>Acknowledgements</title><p id="p0130">The first author would like to thank the following individuals for their support and assistance in this publication: Lauren J. Hassen, Mitchell Ramsey and Katherine Collier.</p><p id="p0135">A preliminary version of this data has previously been presented and published as a conference abstract at the American Heart Association 2020 Scientific Sessions:</p><p id="p0140">Marshall WH, Gee S, Lim W, Bradley EA, Lastinger LT, Daniels CJ, Benza RL, Cackovic M and Rajpal SR. Abstract 15193: Pulmonary Hypertension in Pregnancy: WHO Group 1 Outcomes Improved, Time to Focus on WHO Group 2. Circulation. 2020; 142: A15193.</p></ack><fn-group><fn id="appsec2" fn-type="supplementary-material"><label>Appendix A</label><p id="p0150">Supplementary data to this article can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ijcchd.2022.100354" id="intref0010">https://doi.org/10.1016/j.ijcchd.2022.100354</ext-link>.</p></fn></fn-group></back></article>
